RecruitingPhase 1NCT07215923
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Antidote Therapeutics, Inc
- Principal Investigator
- Matthew Kalnik, PhDAntidote Therapeutics, Inc
- Intervention
- ATI-1013 (0.2 g)(biological)
- Enrollment
- 15 enrolled
- Eligibility
- 23-59 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Dr. Vince Clinical Research, Overland Park, Kansas, United States
Collaborators
National Institute on Drug Abuse (NIDA) · National Institutes of Health (NIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07215923 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07023965Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)Beijing Northland Biotech. Co., Ltd.
- RECRUITINGPHASE4NCT05854615Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's DiseaseCell Biopeutics Resources Sdn Bhd